<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783236</url>
  </required_header>
  <id_info>
    <org_study_id>1204012295</org_study_id>
    <nct_id>NCT01783236</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study the efficacy of FDA approved intravenous (IV) acetaminophen (&quot;Ofirmev&quot;, © 2011
      Cadence Pharmaceuticals, Inc.) in reducing opioid consumption after minimally invasive
      thoracic surgery in a double blind randomized trial. This drug has been shown in Europe to
      reduce the need for patient controlled analgesia and the total dose of opioids, which have
      serious side effects in thoracic surgery patients. We will compare the use of IV
      patient-controlled morphine (PCA) in two groups of subjects in treating postoperative pain.
      We will determine if IV acetaminophen reduces post-operative morphine requirements (primary
      end point). We will also assess subject pain scores and post-operative complications
      associated with pain management as secondary end points. Our hypothesis is that the study arm
      receiving intravenous acetaminophen will have lower total morphine consumptions compared to
      the placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will study the efficacy of FDA approved intravenous (IV) acetaminophen (&quot;Ofirmev&quot;, © 2011
      Cadence Pharmaceuticals, Inc.) in reducing opioid consumption after minimally invasive
      thoracic surgery in a double blind randomized trial. This drug has been shown in Europe to
      reduce the need for patient controlled analgesia and the total dose of opioids, which have
      serious side effects in thoracic surgery patients. We will compare the use of IV
      patient-controlled morphine (PCA) in two groups of subjects in treating postoperative pain.
      One group of subjects will receive IV acetaminophen every six hours beginning within 30
      minutes before surgical end time and continuing for 24 hours plus IV morphine PCA, and the
      other group will receive IV placebo every six hours plus IV morphine PCA, a standard
      treatment for postoperative pain. We will determine if IV acetaminophen reduces
      post-operative morphine requirements (primary end point). We will also assess subject pain
      scores and post-operative complications associated with pain management as secondary end
      points. Our hypothesis is that the study arm receiving intravenous acetaminophen will have
      lower total morphine consumptions compared to the placebo group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Morphine Consumption (mg)</measure>
    <time_frame>24 hours</time_frame>
    <description>How much morphine the subject consumes in the first 24 hours after surgery (mg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of PCA Requests in First 24 Hours Post-Operation</measure>
    <time_frame>24 hours post-operation</time_frame>
    <description>The total number of Patient Controlled Analgesic (PCA) requests in the first 24 hours after the conclusion of the subject's operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain Score 2 Hours Post Operation</measure>
    <time_frame>2 Hours Post Operation</time_frame>
    <description>2 hours after the conclusion of their operation,participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain Score 6 Hours Post-Operation</measure>
    <time_frame>6 Hours Post-Operation</time_frame>
    <description>6 hours after the conclusion of their operation, participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score 24 Hours Post-Operation</measure>
    <time_frame>24 hours post-operation</time_frame>
    <description>24 Hours after the conclusion of the subject's operation, participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lung Tumor</condition>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>1000mg IV Ofirmev given every six hours for a total of four doses.</description>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <other_name>Ofirmev</other_name>
    <other_name>Paracetamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
    <other_name>Normal saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any elective VATS patients with low probability of conversion to thoracotomy as
             determined by surgery.

          -  Ages 18-99

          -  American Society of Anesthesiologists Physical Status I-III, hemodynamically stable

          -  Male or female

        Exclusion Criteria:

          -  Age less than 18.

          -  Patient refusal

          -  High probability of conversion to thoracotomy as determined by surgeon

          -  Conversion of procedure to thoracotomy (subjects will be withdrawn if VATS procedure
             is converted to thoracotomy, as thoracotomy is more invasive and will likely require
             additional analgesia such as neuraxial and regional anesthesia).

          -  Scheduled procedure of VATS Pleurodesis/decortication

          -  History of Interstitial Lung Disease

          -  Emergency case

          -  Known allergy/adverse reaction to acetaminophen, morphine, or fentanyl

          -  History of drug or alcohol abuse

          -  Patients on preoperative analgesic therapy within one week of surgery

          -  Contraindication to self administered morphine (unable to understand PCA)

          -  Need for postoperative mechanical ventilation

          -  Necessary major deviation for intraoperative study protocol as per the discretion of
             the intraoperative attending anesthesiologist

          -  History of congestive heart failure, renal failure, liver failure

          -  Pregnant or breastfeeding women

          -  Weight less than 51 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Hemmings, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022450lbl.pdf</url>
    <description>Label information for acetaminophen (ofirmev)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <results_first_submitted>February 3, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VATS</keyword>
  <keyword>thoracic surgery</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>ofirmev</keyword>
  <keyword>lung surgery</keyword>
  <keyword>thoracoscopic</keyword>
  <keyword>intravenous acetaminophen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline Placebo</title>
          <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
        </group>
        <group group_id="P2">
          <title>IV Acetaminophen</title>
          <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline Placebo</title>
          <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
        </group>
        <group group_id="B2">
          <title>IV Acetaminophen</title>
          <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="13.18"/>
                    <measurement group_id="B2" value="64.6" spread="8.23"/>
                    <measurement group_id="B3" value="61.8" spread="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Morphine Consumption (mg)</title>
        <description>How much morphine the subject consumes in the first 24 hours after surgery (mg).</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
          </group>
          <group group_id="O2">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Morphine Consumption (mg)</title>
          <description>How much morphine the subject consumes in the first 24 hours after surgery (mg).</description>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="21" upper_limit="98"/>
                    <measurement group_id="O2" value="44" lower_limit="23" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of PCA Requests in First 24 Hours Post-Operation</title>
        <description>The total number of Patient Controlled Analgesic (PCA) requests in the first 24 hours after the conclusion of the subject's operation</description>
        <time_frame>24 hours post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
          </group>
          <group group_id="O2">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of PCA Requests in First 24 Hours Post-Operation</title>
          <description>The total number of Patient Controlled Analgesic (PCA) requests in the first 24 hours after the conclusion of the subject's operation</description>
          <units>PCA requests</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="17" upper_limit="144"/>
                    <measurement group_id="O2" value="43" lower_limit="25" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Pain Score 2 Hours Post Operation</title>
        <description>2 hours after the conclusion of their operation,participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
        <time_frame>2 Hours Post Operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
          </group>
          <group group_id="O2">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Pain Score 2 Hours Post Operation</title>
          <description>2 hours after the conclusion of their operation,participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="59" upper_limit="87.5"/>
                    <measurement group_id="O2" value="49" lower_limit="49" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Pain Score 6 Hours Post-Operation</title>
        <description>6 hours after the conclusion of their operation, participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
        <time_frame>6 Hours Post-Operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
          </group>
          <group group_id="O2">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Pain Score 6 Hours Post-Operation</title>
          <description>6 hours after the conclusion of their operation, participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="65" upper_limit="71"/>
                    <measurement group_id="O2" value="39" lower_limit="22.5" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score 24 Hours Post-Operation</title>
        <description>24 Hours after the conclusion of the subject's operation, participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
        <time_frame>24 hours post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
          </group>
          <group group_id="O2">
            <title>IV Acetaminophen</title>
            <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score 24 Hours Post-Operation</title>
          <description>24 Hours after the conclusion of the subject's operation, participants were asked to draw a vertical line on the VAS to indicate their level of pain, which was then converted into millimeters for interpretations. Scores ranged from 0-100mm. VAS pain score identifies two extremes on a 10 centimeter horizontal line; the extremes are labeled &quot;No Pain&quot; (score of 0) and &quot;Worst possible pain&quot; (score of 100).</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="29" upper_limit="67"/>
                    <measurement group_id="O2" value="16.5" lower_limit="9" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hour study treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saline Placebo</title>
          <description>Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
Saline Placebo: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.</description>
        </group>
        <group group_id="E2">
          <title>IV Acetaminophen</title>
          <description>Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
IV Acetaminophen: 1000mg IV Ofirmev given every six hours for a total of four doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inadequate Pain Control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hugh Hemmings, MD, PhD</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>212-746-2953</phone>
      <email>hchemmi@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

